{"id":7458,"date":"2013-06-10T07:01:09","date_gmt":"2013-06-10T11:01:09","guid":{"rendered":"https:\/\/cablemanpro.com\/wallstreetpr\/?p=7458"},"modified":"2013-06-10T07:01:09","modified_gmt":"2013-06-10T11:01:09","slug":"skystar-bio-pharmaceutical-company-nasdaqskbi-shares-declined-by-10-14","status":"publish","type":"post","link":"https:\/\/cablemanpro.com\/wallstreetpr\/skystar-bio-pharmaceutical-company-nasdaqskbi-shares-declined-by-10-14-7458","title":{"rendered":"Skystar Bio Pharmaceutical Company (NASDAQ:SKBI) shares declined by 10.14%"},"content":{"rendered":"<p style=\"text-align: justify;\">Boston, MA 06\/10\/2013 (wallstreetpr) &#8211;\u00a0The share prices of Skystar Bio Pharmaceutical Company (NASDAQ:SKBI) had declined by 10.14 percent to close at $1.33 per share for the end of last trading session on Friday. The shares of the company had been trading in the range of $1.32 to $1.44 during the day, which was observed to be very close to its 52 week low price level of $1.00 per share. The shares of Skystar Bio Pharmaceutical Company (NASDAQ:SKBI) had recorded 52 week low high price level of $2.39 per share.<\/p>\n<p style=\"text-align: justify;\">Skystar Bio Pharmaceutical Company (NASDAQ:SKBI) is primarily engaged in the development and commercialization of pharmaceutical and healthcare products related to veterinary care. The company operates its business through four major segments namely micro organism product line, veterinary medicine line, feed additives line and bio pharmaceutical veterinary vaccine line. All the research and development operations of Skystar Bio Pharmaceutical Company (NASDAQ:SKBI) are carried out through the joint stock company based in the People\u2019s Republic of China in which the company holds contractual ownership.<\/p>\n<p style=\"text-align: justify;\">Skystar Bio Pharmaceutical Company (NASDAQ:SKBI) had recently released the financial results for the first quarter of fiscal year 2013, in which it had reported a net income of $0.7 million which translates into $0.09 gain per basic and diluted share compared to $1.9 million or $0.26 gain per basic and diluted share for the same quarter of previous year.<\/p>\n<p style=\"text-align: justify;\">The shares of Skystar Bio Pharmaceutical Company (NASDAQ:SKBI) had recently been experiencing heavy trading volumes with nearly 37,506 shares being exchanged hands on Friday, while the average trading volume of the company is at 25,244 shares per day. The veterinary care products based bio pharmaceutical company presently holds 7.60 million shares outstanding in the market with an institutional ownership of 4 percent of its holdings.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Boston, MA 06\/10\/2013 (wallstreetpr) &#8211;\u00a0The share prices of Skystar Bio Pharmaceutical Company (NASDAQ:SKBI) had declined by 10.14 percent to close at $1.33 per share for [&hellip;]<\/p>\n","protected":false},"author":6,"featured_media":7459,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"twitter_2902945987_2902945987":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[264],"tags":[2528,2527],"stock_ticker":[],"class_list":["post-7458","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health","tag-nasdaqskbi","tag-skystar-bio-pharmaceutical-company-nasdaqskbi","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Skystar Bio Pharmaceutical Company (NASDAQ:SKBI) shares declined by 10.14% - Wall Street PR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cablemanpro.com\/wallstreetpr\/skystar-bio-pharmaceutical-company-nasdaqskbi-shares-declined-by-10-14-7458\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Skystar Bio Pharmaceutical Company (NASDAQ:SKBI) shares declined by 10.14% - Wall Street PR\" \/>\n<meta property=\"og:description\" content=\"Boston, MA 06\/10\/2013 (wallstreetpr) &#8211;\u00a0The share prices of Skystar Bio Pharmaceutical Company (NASDAQ:SKBI) had declined by 10.14 percent to close at $1.33 per share for [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/skystar-bio-pharmaceutical-company-nasdaqskbi-shares-declined-by-10-14-7458\" \/>\n<meta property=\"og:site_name\" content=\"Wall Street PR\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/WallStreetPR\/\" \/>\n<meta property=\"article:published_time\" content=\"2013-06-10T11:01:09+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/06\/logo.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1024\" \/>\n\t<meta property=\"og:image:height\" content=\"768\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Brendan Byrne\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Brendan Byrne\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/skystar-bio-pharmaceutical-company-nasdaqskbi-shares-declined-by-10-14-7458#article\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/skystar-bio-pharmaceutical-company-nasdaqskbi-shares-declined-by-10-14-7458\"},\"author\":{\"name\":\"Brendan Byrne\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/63a75bf2d685d9d351a6f01cfc69b511\"},\"headline\":\"Skystar Bio Pharmaceutical Company (NASDAQ:SKBI) shares declined by 10.14%\",\"datePublished\":\"2013-06-10T11:01:09+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/skystar-bio-pharmaceutical-company-nasdaqskbi-shares-declined-by-10-14-7458\"},\"wordCount\":294,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/skystar-bio-pharmaceutical-company-nasdaqskbi-shares-declined-by-10-14-7458#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/06\/logo.jpg\",\"keywords\":[\"NASDAQ:SKBI\",\"Skystar Bio \u2013 Pharmaceutical Company (NASDAQ:SKBI)\"],\"articleSection\":[\"Health\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/skystar-bio-pharmaceutical-company-nasdaqskbi-shares-declined-by-10-14-7458#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/skystar-bio-pharmaceutical-company-nasdaqskbi-shares-declined-by-10-14-7458\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/skystar-bio-pharmaceutical-company-nasdaqskbi-shares-declined-by-10-14-7458\",\"name\":\"Skystar Bio Pharmaceutical Company (NASDAQ:SKBI) shares declined by 10.14% - Wall Street PR\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/skystar-bio-pharmaceutical-company-nasdaqskbi-shares-declined-by-10-14-7458#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/skystar-bio-pharmaceutical-company-nasdaqskbi-shares-declined-by-10-14-7458#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/06\/logo.jpg\",\"datePublished\":\"2013-06-10T11:01:09+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/skystar-bio-pharmaceutical-company-nasdaqskbi-shares-declined-by-10-14-7458#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/skystar-bio-pharmaceutical-company-nasdaqskbi-shares-declined-by-10-14-7458\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/skystar-bio-pharmaceutical-company-nasdaqskbi-shares-declined-by-10-14-7458#primaryimage\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/06\/logo.jpg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/06\/logo.jpg\",\"width\":1024,\"height\":768},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/skystar-bio-pharmaceutical-company-nasdaqskbi-shares-declined-by-10-14-7458#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Skystar Bio Pharmaceutical Company (NASDAQ:SKBI) shares declined by 10.14%\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"name\":\"Wall Street PR\",\"description\":\"Latest News From WallStreet\",\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\",\"name\":\"Wall Street PR\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"width\":537,\"height\":70,\"caption\":\"Wall Street PR\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/WallStreetPR\/\",\"https:\/\/x.com\/WallstreetPRs\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/63a75bf2d685d9d351a6f01cfc69b511\",\"name\":\"Brendan Byrne\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/c07a17b7438044417a1ad0f7933a311fcc2a96eaf4b15f2599b0fdfb37cbda41?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/c07a17b7438044417a1ad0f7933a311fcc2a96eaf4b15f2599b0fdfb37cbda41?s=96&d=mm&r=g\",\"caption\":\"Brendan Byrne\"},\"description\":\"While studying economics, Brendan found himself comfortably falling down the rabbit hole of restaurant work, ultimately opening a consulting business and working as a private wine buyer. On a whim, he moved to China, and in his first week following a triumphant pub quiz victory, he found himself bleeding on the floor based on his arrogance. The same man who put him there offered him a job lecturing for the University of Wales in various sister universities throughout the Middle Kingdom. While primarily lecturing in descriptive and comparative statistics, Brendan simultaneously earned an Msc in Banking and International Finance from the University of Wales-Bangor. He's presently doing something he hates, respecting French people. Well, two, his wife and her mother in the lovely town of Antigua, Guatemala. You may contact Brendan via his email (brendanbyrne@cablemanpro.com) or his Google+ page (https:\/\/plus.google.com\/u\/0\/116608759701551457422).\",\"sameAs\":[\"https:\/\/cablemanpro.com\/wallstreetpr\"],\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/author\/brendan-byrne\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Skystar Bio Pharmaceutical Company (NASDAQ:SKBI) shares declined by 10.14% - Wall Street PR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cablemanpro.com\/wallstreetpr\/skystar-bio-pharmaceutical-company-nasdaqskbi-shares-declined-by-10-14-7458","og_locale":"en_US","og_type":"article","og_title":"Skystar Bio Pharmaceutical Company (NASDAQ:SKBI) shares declined by 10.14% - Wall Street PR","og_description":"Boston, MA 06\/10\/2013 (wallstreetpr) &#8211;\u00a0The share prices of Skystar Bio Pharmaceutical Company (NASDAQ:SKBI) had declined by 10.14 percent to close at $1.33 per share for [&hellip;]","og_url":"https:\/\/cablemanpro.com\/wallstreetpr\/skystar-bio-pharmaceutical-company-nasdaqskbi-shares-declined-by-10-14-7458","og_site_name":"Wall Street PR","article_publisher":"https:\/\/www.facebook.com\/WallStreetPR\/","article_published_time":"2013-06-10T11:01:09+00:00","og_image":[{"width":1024,"height":768,"url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/06\/logo.jpg","type":"image\/jpeg"}],"author":"Brendan Byrne","twitter_misc":{"Written by":"Brendan Byrne","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/skystar-bio-pharmaceutical-company-nasdaqskbi-shares-declined-by-10-14-7458#article","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/skystar-bio-pharmaceutical-company-nasdaqskbi-shares-declined-by-10-14-7458"},"author":{"name":"Brendan Byrne","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/63a75bf2d685d9d351a6f01cfc69b511"},"headline":"Skystar Bio Pharmaceutical Company (NASDAQ:SKBI) shares declined by 10.14%","datePublished":"2013-06-10T11:01:09+00:00","mainEntityOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/skystar-bio-pharmaceutical-company-nasdaqskbi-shares-declined-by-10-14-7458"},"wordCount":294,"commentCount":0,"publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/skystar-bio-pharmaceutical-company-nasdaqskbi-shares-declined-by-10-14-7458#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/06\/logo.jpg","keywords":["NASDAQ:SKBI","Skystar Bio \u2013 Pharmaceutical Company (NASDAQ:SKBI)"],"articleSection":["Health"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/cablemanpro.com\/wallstreetpr\/skystar-bio-pharmaceutical-company-nasdaqskbi-shares-declined-by-10-14-7458#respond"]}]},{"@type":"WebPage","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/skystar-bio-pharmaceutical-company-nasdaqskbi-shares-declined-by-10-14-7458","url":"https:\/\/cablemanpro.com\/wallstreetpr\/skystar-bio-pharmaceutical-company-nasdaqskbi-shares-declined-by-10-14-7458","name":"Skystar Bio Pharmaceutical Company (NASDAQ:SKBI) shares declined by 10.14% - Wall Street PR","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/skystar-bio-pharmaceutical-company-nasdaqskbi-shares-declined-by-10-14-7458#primaryimage"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/skystar-bio-pharmaceutical-company-nasdaqskbi-shares-declined-by-10-14-7458#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/06\/logo.jpg","datePublished":"2013-06-10T11:01:09+00:00","breadcrumb":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/skystar-bio-pharmaceutical-company-nasdaqskbi-shares-declined-by-10-14-7458#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cablemanpro.com\/wallstreetpr\/skystar-bio-pharmaceutical-company-nasdaqskbi-shares-declined-by-10-14-7458"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/skystar-bio-pharmaceutical-company-nasdaqskbi-shares-declined-by-10-14-7458#primaryimage","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/06\/logo.jpg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/06\/logo.jpg","width":1024,"height":768},{"@type":"BreadcrumbList","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/skystar-bio-pharmaceutical-company-nasdaqskbi-shares-declined-by-10-14-7458#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cablemanpro.com\/wallstreetpr\/"},{"@type":"ListItem","position":2,"name":"Skystar Bio Pharmaceutical Company (NASDAQ:SKBI) shares declined by 10.14%"}]},{"@type":"WebSite","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","name":"Wall Street PR","description":"Latest News From WallStreet","publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization","name":"Wall Street PR","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","width":537,"height":70,"caption":"Wall Street PR"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/WallStreetPR\/","https:\/\/x.com\/WallstreetPRs"]},{"@type":"Person","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/63a75bf2d685d9d351a6f01cfc69b511","name":"Brendan Byrne","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/c07a17b7438044417a1ad0f7933a311fcc2a96eaf4b15f2599b0fdfb37cbda41?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/c07a17b7438044417a1ad0f7933a311fcc2a96eaf4b15f2599b0fdfb37cbda41?s=96&d=mm&r=g","caption":"Brendan Byrne"},"description":"While studying economics, Brendan found himself comfortably falling down the rabbit hole of restaurant work, ultimately opening a consulting business and working as a private wine buyer. On a whim, he moved to China, and in his first week following a triumphant pub quiz victory, he found himself bleeding on the floor based on his arrogance. The same man who put him there offered him a job lecturing for the University of Wales in various sister universities throughout the Middle Kingdom. While primarily lecturing in descriptive and comparative statistics, Brendan simultaneously earned an Msc in Banking and International Finance from the University of Wales-Bangor. He's presently doing something he hates, respecting French people. Well, two, his wife and her mother in the lovely town of Antigua, Guatemala. You may contact Brendan via his email (brendanbyrne@cablemanpro.com) or his Google+ page (https:\/\/plus.google.com\/u\/0\/116608759701551457422).","sameAs":["https:\/\/cablemanpro.com\/wallstreetpr"],"url":"https:\/\/cablemanpro.com\/wallstreetpr\/author\/brendan-byrne"}]}},"_links":{"self":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/7458","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/comments?post=7458"}],"version-history":[{"count":0,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/7458\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media\/7459"}],"wp:attachment":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media?parent=7458"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/categories?post=7458"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/tags?post=7458"},{"taxonomy":"stock_ticker","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/stock_ticker?post=7458"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}